Volume 2 Issue 1

Research Article

Anti-Endomysial Antibody May Predict a Second Endoscopy in Coeliac-Suspected Patients with False Negative Index Duodenal Biopsies

Authors: Gerada J, Gerada E, Abdilla S, Grech G and Ellul P

Type: Research Article   

Special Article - Digestive Endoscopy

Sedation and Monitoring for Gastrointestinal Endoscopy: Worldwide Attitudes and Evidence

Authors: Fanti Lorella, Gemma Marco, Gemma Rossi, Agostoni Massimo and Testoni Pier Alberto

Type: Special Article - Digestive Endoscopy   

Special Article - Digestive Endoscopy

Determination of Helicobacter pylori Virulence Genes in Clinical Isolates of Symptomatic Patients from South Coastal Region of Karnataka - A Preliminary Work

Authors: Shetty V, Ballal M, Lingadakai R and Mukhopadhyay A

Type: Special Article - Digestive Endoscopy   

Special Article - Inflammatory Bowel Disease

Poor Agreement between Preoperative Biopsies and Pathological Resection Findings in IBD-Associated Dysplasia

Authors: Althumairi AA, Monn MF, Derck JE, Wick EC, Efron JE, Lazarev MG, Montgomery EA, Gearhart SL

Type: Special Article - Inflammatory Bowel Disease   

Clinical Image

Rare Cause of Uncomplicated Gas-forming Pyogenic Liver Abscess

Authors: Nijhawan S, Singh B, Kumar A, Gupta G

Type: Clinical Image   

Clinical Image

Bridging Pancreatic Duct Stent - A Rare Adverse Event

Authors: Arya V, Bansal V and Kabul V

Type: Clinical Image   

Published Manuscripts

Impact Factor: 2.8


 About the Journal  

Austin Journal of Gastroenterology is an open access, peer reviewed, scholarly journal dedicated to publish articles related to original and latest advancement of in the field of Gastroenterology.

The aim of this journal is to provide a platform for research scholars and academicians around the globe to promote, share, and discuss various new issues and developments in different fields of

Featured Article

Safety Profile of Anti-TNF Agents in Polish Pediatric Patients with Crohn’s Disease

Abstract In recent years, monoclonal antibodies against TNF-alpha, infliximab (IFX) and Adalimumab, have been gaining increasing popularity in Crohn’s disease (CD) management.

© 2014 Austin Publications LLC